Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Other solid neoplasm 1Gastrointestinal 1

Conditions

Sarcoma 1Pancreatic Neoplasms 1Osteosarcoma 1Oligodendroglioma 1Mesothelioma, Malignant 1Lung Neoplasms 1Gliosarcoma 1Glioblastoma 1Chondrosarcoma 1Central Nervous System Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Brain Neoplasms 1Astrocytoma 1

Interventions

Doxorubicin 142Ifosfamide 85Radiotherapy 82Cyclophosphamide 72Gemcitabine 63Filgrastim 54pembrolizumab 43pazopanib 40Etoposide 39Docetaxel 39Vincristine 37Trabectedin 37Cisplatin 35Nivolumab 32Magnetic Resonance Spectroscopy 26Irinotecan 26Carboplatin 25Temozolomide 23Surgical Procedures, Operative 23Radiation 22Ipilimumab 22Bevacizumab 20Blood Specimen Collection 19Granulocyte Colony-Stimulating Factor 18Biopsy 18eribulin 17Sirolimus 17Mesna 17Melphalan 17Dactinomycin 17

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × alanosine × Clear all
NCT00062283 2013-06-26

Alanosine in Treating Patients With Cancer

National Cancer Institute (NCI)

Phase 2 Completed
GastrointestinalOther solid neoplasmSarcomaThoracic

Mesothelioma, Malignant, Carcinoma, Non-Small-Cell Lung, Chondrosarcoma, Lung Neoplasms, Pancreatic Neoplasms, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡